Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized prostate cancer, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 13th Annual BIO Investor Forum. The presentation is scheduled for Tuesday, October 7, 2014 at 8:00 a.m. PDT in San Francisco.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
